Novartis’s Beovu Launch Clouded By Safety Worries
Beovu Uncertainty Should Benefit Regeneron’s Eylea
New safety concerns over Novartis's anti-VEGF eye injection drug will likely cut its uptake and reduce its competitive threat to Bayer and Regeneron's VEGF inhibitor Eylea.
You may also be interested in...
Despite the impact from COVID-19, Novartis performed strongly in the second quarter "demonstrating resilience and agility of our associates and operations," according to CEO Vas Narasimhan. However, there is cause for concern at its ophthalmogy business and those problems are certainly not all down to coronavirus.
The pandemic is expected to dominate the industry's second quarter earnings calls, which kick off on 16 July, but here are 10 other topics to listen for.
The company reported strong 33% revenue growth in Q1, despite softer Eylea sales from postponed treatments, progressed in oncology, and is moving an antibody cocktail for COVID-19 into clinical testing.